{"id":"W3131063362","doi":"10.1056/nejmoa2035716","title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1761,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Western University; University Hospital Foundation","funders":"Merck Sharp and Dohme; National Cancer Institute; Eisai","keywords":"Lenvatinib; Pembrolizumab; Everolimus; Sunitinib; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03799850471779221,"score_gpt":0.294172294434195,"score_spread":0.2561737897164028,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}